Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: Vaccine. 2020 May 6;38(29):4601–4608. doi: 10.1016/j.vaccine.2020.05.009

Figure 2.

Figure 2.

Impact of vaccination with VLP and adjuvants on Ebola vims challenge after a single vaccination and after two immunizations in response to delayed challenge. C57BL/6 mice were vaccinated on Day 0 with VLP (1.25 μg GP) in combination with adjuvants (1 mg Advax-2 or -4 or 10 μg pICLC) and then challenged with 1000 pfu of mouse adapted (ma)-Ebola vims IP on day 28 (p-value based on Log-rank Mantel-Cox test, <0.005 for all adjuvants in comparison to eVLP alone) (A). C57BL/6 mice were vaccinated on Day 0 and 21 with VLP (1.25 μg GP) with adjuvants (Advax-2 or -4 or pICLC) and then challenged with 1000 pfu of mouse adapted (ma)-Ebola vims IP on day 177 (p-value based on Log-rank Mantel-Cox test, <0.005 for all adjuvants in comparison to eVLP alone) (B). Anti-GP titers from samples collected at various time points after vaccination and boost (p-value based on 2 way ANOVA in comparison to eVLP alone, * = p<0.05, ** = p<0.005, *** = p< 0.0005, **** = p<0.0001) (C-F).